1[1]Sahin AA. Biologic and clinical significance of HER- 2/ neu ( cerbB- 2) in breast cancer. Adv Anat Pathol, 2000,7( 3) : 158- 166. 被引量：1
2[2]Beth Strauss BS MS BSN/ MSNc, Best hope or last hope access to phase Ⅲ clinical trials of HER- 2/ neu for advanced stage breast cancer patients. Journal of Advanced Nursing, 2000, 31( 2) :259- 266. 被引量：1
3[3]Yu D, Hung MC. Role of erbB2 in breast cancer chemosensitivity. Ann Oncol, 2000 Jun,11( 6) : 647- 663. 被引量：1
4[4]Ciocca DR,Elledge R. Molecular markers for predicting response to tamoxifen in breast cancer patients. Endocrine, 2000, Aug,13( 1) : 1- 10. 被引量：1
5[5]Hamilton A, Piccart M. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER- 2, p53 and BCL- 2. Ann Oncol, 2000, Jun, 11( 6) : 647- 63. 被引量：1
6[6]Gilewski T, Seidman A, Norton L, et al. An immunotherapeutic approach to treatment of breast cancer: focus on trastuzumab plus paclitaxel. Breast Cancer Medicine Service, Cancer Chemother Pharmacol, 2000, 46, Suppl( 1) : 523- 526. 被引量：1
7[7]Pegram MD, Konecny G, Slamon DJ. The molecular and cellular biology of HER2/new gene amplification/ overexpression and the clinical development of herceptin ( trastuzumab) therapy for breast cancer.Cancer Treat Res, 2000,103( 1) : 57- 75. 被引量：1
8[8]Burris HA. Docetaxel (Taxotere) in HER- 2- positive patients and in combination with trastuzumab ( Herceptin).Semin Oncol, 2000, Apr, 27( 2 Suppl 3) : 19- 23. 被引量：1
9[9]Wei- zen Wei, Wei- ping Shi, Anne Galy, et al. Protection against mammary tumor growth by vaccination with full- length, modified human ErbB- 2 DNA. Int. J. Cancer, 1999, 81: 748- 754. 被引量：1
